Organization
University of Cologne
14 clinical trials
6 abstracts
Abstract
Tolerability and efficacy of BrECADD versus BEACOPP in advanced stage classical Hodgkin lymphoma: GHSG HD21, a randomized study.Org: University Hospital of Cologne, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), German Hodgkin Study Group (GHSG), Swiss Group for Clinical Cancer Research (SAKK), Department of Internal Medicine III with Hematology,
Clinical trial
Open-label, Single Arm Phase II Trial Investigating the Efficacy, Safety and Quality of Life of Neoadjuvant Chemotherapy With Liposomal Irinotecan Combined With Oxaliplatin and 5-Fluorouracil/Folinic Acid Followed by Curative Surgical Resection in Patients With Hepatic Oligometastatic Adenocarcinoma of the PancreasStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Phase 2 Trial of Metronomic Treatment in Children and Adolescents With Recurrent or Progressive Neuroblastoma (NB)Status: Completed, Estimated PCD: 2023-06-29
Clinical trial
A Multicenter Phase II Trial of Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in Homologous Recombination Deficiency (HRD) Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC)Status: Not yet recruiting, Estimated PCD: 2026-09-01
Clinical trial
Phase II Trial of Pembrolizumab in First-Line Treatment of Advanced-Stage Classical Hodgkin LymphomaStatus: Not yet recruiting, Estimated PCD: 2025-01-01
Clinical trial
Platelet Response to Caplacizumab in the Treatment of Acquired Thrombotic Thrombocytopenic PurpuraStatus: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
HD21 for Advanced Stages Treatment Optimization Trial in the First-line Treatment of Advanced Stage Hodgkin Lymphoma; Comparison of 6 Cycles of Escalated BEACOPP With 6 Cycles of BrECADDStatus: Active (not recruiting), Estimated PCD: 2022-12-01
Clinical trial
A Phase 1/2a Trial of the Intravenous Administration of the SARS-CoV-2-Neutralizing Monoclonal Antibody DZIF-10c in SARS-CoV-2-Infected and -Uninfected IndividualsStatus: Completed, Estimated PCD: 2021-08-11
Clinical trial
An Open-label, Multicenter, Phase I Dose-escalation Trial of EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer and Acquired EGFR p.T790M-positive Resistance to 1st or 2nd Generation EGFR TKI Therapy Remark: According to Version V02_0 of the Protocol, Patients May Also be Eligible if EGFR TKI-treatment naïve, EGFR p.T790M-negative at Progression While on EGFR TKI Therapy or After Progression While on Osimertinib TreatmentStatus: Completed, Estimated PCD: 2022-09-30
Clinical trial
A Phase II Trial to Evaluate Safety and Efficacy of Adding Durvalumab (MEDI4736) to Standard Neoadjuvant Radiochemotherapy and of Adjuvant Durvalumab +/- Tremelimumab in Locally Advanced Esophageal Adenocarcinoma and to Evaluate Biomarkers Predictive for Response to Immune Checkpoint InhibitionStatus: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
Pilot-trial of Methotrexate, Tafasitamab (Minjuvi®), Lenalidomide (Revlimid®) and Rituximab in Patients Ineligible for HCT-ASCT With Primary Central Nervous System Lymphoma (PCNSL)Status: Not yet recruiting, Estimated PCD: 2027-02-01
Clinical trial
Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin LymphomaStatus: Not yet recruiting, Estimated PCD: 2025-12-01
Clinical trial
Nivolumab and AVD in Early-stage Unfavorable Classical Hodgkin LymphomaStatus: Active (not recruiting), Estimated PCD: 2023-12-01
Clinical trial
Retrospective Analysis of the Efficiency of Caplacizumab in the Treatment of Acquired Thrombotic Thrombocytopenic Purpura (aTTP)- REACT-2020Status: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
Phase II Trial of TisaGenlecleucel in Elderly Patients With First-Relapsed or Primary Refractory Aggressive B-cell Non-Hodgkin LymphomaStatus: Terminated, Estimated PCD: 2023-02-24
Abstract
Incidence and survival of oropharyngeal carcinoma patients and the development of HPV-testing prevalence in North Rhine-Westphalia: A Cancer Registry analysis from 2008-2018.Org: University of Duisburg/Essen, Cancer Registry North Rhine-Westphalia, Cancer Registry of North Rhine-Westphalia, West German Cancer Center, University Hospital Essen, University Hospital Essen,
Abstract
The evolving value assessment of cancer therapies: Principles from the cancer community.Org: The Boston Consulting Group, Lung cancer Europe, The Susan G. Komen Breast Cancer Foundation, Inc., Cancer Technology Applications, International Breast Cancer Centre (IBCC),
Abstract
Clinical characteristics and treatment outcome of patients with advanced non-small-cell lung cancer (NSCLC) and FGFR fusions.Org: University of Cologne, University Hospital Cologne Center for Integrated Oncology, Institute for Pathology, Department of Translational Genomics, Network Genomic Medicine,
Abstract
Class II and class III BRAF mutations in patients with advanced non-small cell lung cancer (NSCLC): Clinical characteristics, mutation patterns, and survival outcomes.Org: Network Genomic Medicine, University Hospital of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne,
Abstract
ANAKINRA (IL1-RA) IN THE TREATMENT OF PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS REFRACTORY TO OR INTOLERANT OF METHOTREXATE (MTX)Org: Department of Internal Medicine I, Medical University of Vienna, Department of Dermatology, Department of Internal Medicine II, University of Cologne, Cologne, Germany,